Trial Profile
A Multicentre, Open-label, Three-arm Randomised Phase II Trial Assessing the Safety and Efficacy of the HSP90 Inhibitor Ganetespib in Combination With Carboplatin Followed by Maintenance Treatment With Niraparib Versus Ganetespib Plus Carboplatin Followed by Ganetespib and Niraparib Versus Carboplatin in Combination With Standard Chemotherapy Followed by Niraparib Maintenance Treatment in Platinum-sensitive Ovarian Cancer Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Ganetespib (Primary) ; Niraparib (Primary) ; Gemcitabine; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Sarcoma
- Focus Therapeutic Use
- Acronyms EUDARIO
- 23 Sep 2023 The trial has been completed in Belgium and Germany , according to European Clinical Trials Database record.
- 14 Sep 2023 Status changed from active, no longer recruiting to completed.
- 24 Apr 2023 The trial has been completed in Austria, according to European Clinical Trials Database record.